Patients with HCV genotype 2 have a very high likelihood of sustained virologic response with sofosbuvir and ribavirin, and therefore treatment should be initiated with these agents.
If you want to change selection, open document below and click on "Move attachment"
- (no access) - MKSAP_17.pdf, p2687
|status||not read|| ||reprioritisations|
|last reprioritisation on|| ||suggested re-reading day|
|started reading on|| ||finished reading on|